StreetAlpha.app
Home › Stocks › ARTV

Artiva Biotherapeutics, Inc. (ARTV)

Healthcare
$3.86
▼ −2.53%
LAST CLOSE · NOV 17

Artiva develops natural killer cell therapies for autoimmune diseases and cancers, based in San Diego, California. It last closed at $3.86 on Nov 17, down 2.53% on the day. The average 12-month price target from 2 analysts is $4.00 (+3.6% from the last close), with a high of $4.00 and a low of $4.00. In the past 30 days there were 2 dark pool prints totaling $2.2M, the largest $2.1M.

AI Auto Pilots
Is ARTV in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$83.9M
EPS (diluted)
−$3.43
Free cash flow
−$79.3M
Valuation
Market cap
$190.8M
49.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$61.2M
At Sep 30
Shareholder equity
$320.7M
Shares outstanding
49.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $33.5M$33.5MFY2023FY2024: $251K$251KFY2024FY2025: $0$0FY2025

From ARTV's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 9).

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Hold
2firms
0 Buy2 Hold0 Sell
Only 2 firms rated ARTV in the past 90 days, not enough for a consensus
Average 12-month target
$4.00
▲ 3.6% upside

Based on 2 analysts who set a price target on ARTV in the past 90 days. The average target is $4.00, with a high of $4.00 and a low of $4.00, compared with the last close of $3.86.

Low $4.00Avg $4.00High $4.00
Blue marker: last close $3.86
Highest target$4.00
Average target$4.00
Lowest target$4.00
Latest rating changes
JefferiesDowngrade
Oct 29Hold$4
WedbushDowngrade
Oct 27Hold$4
NeedhamReiterated
Jun 8Buy$41
DateFirmActionRatingPrice target
Oct 29JefferiesDowngradeHold$4
Oct 27WedbushDowngradeHold$4
Jun 8NeedhamReiteratedBuy$41
Loading…

Technical Analysis

ARTV · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 18% below its 20 day and 65% below its 50 day average. It is 107% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the Pivot S1 at $3.78, and the nearest resistance the Pivot at $3.89.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityLow, 7.2%/day
Key levels
$14.5352 week high+276.4%
$8.48100 day average+119.7%
$8.00200 day average+107.3%
$6.3750 day average+65.0%
$4.5520 day average+17.9%
$4.27Swing high (Nov 4)+10.6%
$3.96Pivot R1+2.6%
$3.89Pivot+0.8%
$3.86Last close
$3.78Pivot S1−2.1%
$2.9652 week low−23.3%
Indicators
RSI (14)21.38Oversold below 30Oversold
MACD-0.74Above its signal lineBullish
Stochastic13.3Near the bottom of its rangeOversold
ADX (14)59.6Strong downtrend
Williams %R-89.1Oversold below −80, overbought above −20Oversold
CCI (20)-65.4Oversold below −100, overbought above 100Neutral
Rate of change−8.1%Change over 10 sessionsBearish
ATR (14)$0.28Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARTV

What happened before

See how ARTV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in ARTV in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.2M
Largest print
$2.1M
Loading…

ARTV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲62 buying vs 21 selling
  • ▲Held by funds +1.0 pts
  • ▲Funds holding +26
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9872+36.1%
In funds' top 1023−33.3%
Held by funds83.3%82.3%+1.0 pts
New / increased32 / 3039 / 25−3.1%
Reduced / sold out15 / 62 / 7+133.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARTV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARTV is in one of them and how their past ARTV trades turned out.

ARTV in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARTV in an article yet. Here's the latest on the wider market.

About Artiva Biotherapeutics

Artiva is a biotechnology company based in San Diego, California, that is developing cell therapies made from natural killer cells, a type of immune cell. Its lead product candidate, AlloNK, is made from donor cells, frozen and shipped ready for use, and is designed to work alongside antibody medicines to deplete B cells. The company is testing AlloNK in clinical trials for autoimmune diseases such as rheumatoid arthritis and Sjögren's disease, and it also has programs aimed at cancers. The intended patients are people with these conditions, and the product is not yet approved for sale.

Headquarters
San Diego, CA